Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. History: fetal loss and LAC
4. The use of anti-cardiolipin antigen
5. GPL and past obstetric history
6. International lupus congress NY 2002
7. The primary antiphospholipid syndrome (pAPS)
8. Causes of thromboses in SLE
9. Congenital thrombophilias
10. APS classification criteria (1)
11. Sapporo 1998 conference
12. APS classification criteria (2)
13. APS classification criteria (3)
14. LACs
15. Anti-cardiolipin test (aCL)
16. Autoimmunity
17. Lupus and APS
18. APS is related to LAC, aCL, anti-beta 2GP-I
19. Frequency of aPL
20. Systemic APS
21. The Euro PL study
22. Thrombotic microangiopathy (MAPS)
23. Clinical presentations of APS
24. The Lucio phenomenon
25. Ginsberg study, blood 1992
26. Targets: action
27. Pathogenic mechanisms
28. Pathogenesis data from animal models
29. Passive and active transfer of APS
30. Pathogenesis of obstetric APS (1)
31. Pathogenesis of obstetric APS (2)
32. CNS involvement in APS
33. Snnedon's syndrome
34. Neural injury pathogenesis in APS animal models
35. Cardiopulmonary clinical presentation
36. Importance of BP control in APS
37. Impact of hypertension and hyperhomocysteinemia
38. Management of APS
39. Asymptomatic aPL
40. Thrombosis treatment
41. INR recommendations
42. The importance of INR monitoring
43. APS patients should maintain a monotonous diet
44. Thrombocytopenia
45. Obstetric management of APS
46. Pregnancy: thrombosis and aPL
47. Results from hospital university Pedro Ernesto
48. Advantages and disadvantages of heparin
49. Pregnancy and coumadin; clinical study (1)
50. Pregnancy and coumadin; clinical study (2)
51. Pregnancy and coumadin; clinical study (3)
52. APS and preeclampsia
53. HCQ in SLE pregnancy: clinical study
54. Thrombocytopenia during pregnancy
55. Catastrophic APS
56. Alternative therapies
57. Thromboses prevention
58. Second hit
59. Triggering factors
60. Case study: 29 year old woman with pAPS
61. Vaccination as an APS triggering factor
62. Thromboembolism and antipsychotics
63. Lung adenocarcinoma and thrombosis (1)
64. Lung adenocarcinoma and thrombosis (2)
65. The future of APS treatment
66. APS: messages
67. There is still a lot to learn
68. Ethical issues
69. Acknowledgements
70. The 14'th international APS congress

Topics Covered

• History: fetal loss and LAC
• The use of anti-cardiolipin antigen
• GPL and past obstetric history
• The primary antiphospholipid syndrome (pAPS)
• Causes of thromboses in SLE
• Congenital thrombophilias
• APS classification criteria
• Anti-cardiolipin test (aCL)
• Autoimmunity
• Lupus and APS
• Thrombotic microangiopathy (MAPS)
• The Lucio phenomenon
• Pathogenesis
• CNS involvement in APS
• Snnedon's syndrome
• Neural injury pathogenesis in APS animal models
• Management of APS
• Asymptomatic aPL
• Thrombosis treatment
• INR recommendations
• Thrombocytopenia
• Obstetric management of APS
• Advantages and disadvantages of heparin
• Pregnancy and coumadin; clinical study
• APS and preeclampsia
• HCQ in SLE pregnancy: clinical study
• Thrombocytopenia during pregnancy
• Catastrophic APS
• Alternative therapies
• Vaccination as an APS triggering factor
• Thromboembolism and antipsychotics
• Lung adenocarcinoma and thrombosis
• The future of APS treatment
• Ethical issues

Links

Series:

• Autoimmunity

Categories:

• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Levy, R. (2010, February 9). Antiphospholipid syndrome (APS): from pathogenesis to treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/MBPV5986.
Export Citation (RIS)

Publication History

• Published on February 9, 2010

Financial Disclosures

• Prof. Roger Levy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.